Veravas launched in 2017 with a mission that went far beyond just selling technology or building products. We want to impact healthcare, raising the bar for diagnostic accuracy, efficacy, and the scope of what can be tested. Below are some milestones and inflection points in this journey.
Charleston, SC (April 16, 2020) - True Diagnostics, Inc. (TrueDx), a leading Point of Care (POC)company, Infectolab Americas (Infectolab), a recently established CLIA laboratory specializingin comprehensive testing for tick-born infection, and Veravas, Inc. (Veravas), an emergingdiagnostic company focusing on proprietary sample preparation products and new diagnostic tests,announced today their Strategic Alliance to develop and commercialize VeraTest™ SARS-CoV-2 IgA/IgG Rapid Test.
Veravas, Inc., an emerging diagnostic company focusing on sample preparation products and new diagnostic tests and MIP Diagnostics Ltd., the Molecularly Imprinted Polymers (MIPs) specialist based in Sharnbrook, United Kingdom, announced today that they have entered into a mutually beneficial agreement for the development, license, and supply of a novel MIP specific for Veravas’ proprietary sample preparation technology.
Register to receive updates and more information as it becomes available – from product launches to conference posters to novel partnerships and events.